title: Treating glioblastoma patients with poor performance status: where do we go from here?
abstract: Approximately one third of all glioblastoma patients exhibit an impaired functional status in the perioperative setting. Their optimal management is difficult to define. The only available prospective study in poor performance status (PS) patients has been performed in elderly patients (≥ 70 years). In this population, treatment with temozolomide was shown to be safe and to be associated with a clinically significant improvement of PS in one third of patients. In young patients (<70 years), daily clinical experience and retrospective data show that some patients can benefit from temozolomide radiochemotherapy, abbreviated radiation courses, upfront chemotherapy or early use of bevacizumab. However, prospective studies are needed to correctly evaluate these strategies, namely their impact on functional status and quality of life.
authors: Department of Neurology, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
authors: Jaime
authors: J
authors: Gállego Pérez-Larraya
authors: François
authors: F
authors: Ducray
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005909:Glioblastoma / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D011379:Prognosis
keywords: Karnofsky performance score; glioblastoma; poor performance status